I like to get this clarified. My understanding is Grandcimab is not such a game changer. I think CSL already has products in the market and therefore there will be some loss of income from those. I have seen $50 being mentioned and that is a just an estimate of the value of R&D budget CSL keeps spending. Try to monetise. I am sure someone in this group can confirm which is correct.
CSL112, page-5
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$285.10 |
Change
-6.060(2.08%) |
Mkt cap ! $138.0B | |||
| Open | High | Low | Value | Volume |
| $289.85 | $291.99 | $285.10 | $215.2M | 748.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2976 | $285.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $286.53 | 75 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |